Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | VPS4B | O75351 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HTR1E | P28566 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560415 | 0.87 | HTR1A (0.44) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8116284 | 0.85 | HTR1F (0.42) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| Acetic Acid SCHEMBL8555874 | 0.83 | ALDH1A1 (0.42) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8116526 | 0.79 | HTR1F (0.51) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8109535 | 0.78 | HTR1F (0.47) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8116663 | 0.78 | JAK2 (0.46) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8114970 | 0.76 | F2R (0.46) | HTR1FALDH1A1LMNAHTR1AVPS4B | |
| SCHEMBL8109460 | 0.74 | VPS4B (0.39) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL8110515 | 0.72 | HTR1A (0.43) | HTR1FALDH1A1LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL8101396 | 0.72 | VPS4B (0.42) | HTR1FALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| US-5814653-A | SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5708187-A | MIGRANE HEADACHES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0749962-A1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885ALDH1A1 563/4885LMNA 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.